IOVA

Iovance Biotherapeutics, Inc. develops and delivers tumor infiltrating lymphocyte (TIL) therapies for cancer treatment. The company focuses on harnessing the human immune system to target and destroy cancer cells, with a commitment to innovation in cell therapy, including gene-edited therapies. Iovance operates primarily in the biotechnology sector, serving patients with various solid tumors, and has facilities in San Carlos, California; Tampa, Florida; and Philadelphia, Pennsylvania.